|
|
Volumn 93, Issue 13, 2001, Pages 970-973
|
|
STI571 revolution: Can the newer targeted drugs measure up?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE;
7 HYDROXYSTAUROSPORINE;
AKT;
ANTINEOPLASTIC AGENT;
BCR ABL PROTEIN;
EPIDERMAL GROWTH FACTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
GEFITINIB;
IMATINIB;
MITOGEN ACTIVATED PROTEIN KINASE;
PLATELET DERIVED GROWTH FACTOR;
PROTEIN KINASE C;
PROTEIN TYROSINE KINASE;
PROTEIN TYROSINE KINASE INHIBITOR;
STEM CELL FACTOR;
TEMSIROLIMUS;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
ARTICLE;
BLAST CELL CRISIS;
BREAST CANCER;
CHROMOSOME TRANSLOCATION;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG MECHANISM;
GASTROINTESTINAL TUMOR;
GENETIC STABILITY;
HUMAN;
ONCOGENE NEU;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PHILADELPHIA 1 CHROMOSOME;
PLASTICITY;
PRIORITY JOURNAL;
|
|
EID: 0035806490
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/93.13.970 Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|